X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs LUPIN LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA LUPIN LTD CIPLA/
LUPIN LTD
 
P/E (TTM) x 44.3 22.8 194.6% View Chart
P/BV x 3.9 3.1 125.3% View Chart
Dividend Yield % 0.3 0.8 40.9%  

Financials

 CIPLA   LUPIN LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
LUPIN LTD
Mar-17
CIPLA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs6221,750 35.5%   
Low Rs4581,384 33.1%   
Sales per share (Unadj.) Rs181.9387.4 46.9%  
Earnings per share (Unadj.) Rs12.956.6 22.7%  
Cash flow per share (Unadj.) Rs29.376.8 38.2%  
Dividends per share (Unadj.) Rs2.007.50 26.7%  
Dividend yield (eoy) %0.40.5 77.4%  
Book value per share (Unadj.) Rs155.7298.9 52.1%  
Shares outstanding (eoy) m804.51451.58 178.2%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x3.04.0 73.4%   
Avg P/E ratio x42.027.7 151.7%  
P/CF ratio (eoy) x18.420.4 90.4%  
Price / Book Value ratio x3.55.2 66.2%  
Dividend payout %15.513.2 117.3%   
Avg Mkt Cap Rs m434,516707,513 61.4%   
No. of employees `00023.016.8 137.2%   
Total wages/salary Rs m26,33828,495 92.4%   
Avg. sales/employee Rs Th6,349.110,418.3 60.9%   
Avg. wages/employee Rs Th1,143.01,697.0 67.4%   
Avg. net profit/employee Rs Th449.31,523.0 29.5%   
INCOME DATA
Net Sales Rs m146,302174,943 83.6%  
Other income Rs m2,2871,065 214.7%   
Total revenues Rs m148,589176,008 84.4%   
Gross profit Rs m24,75844,931 55.1%  
Depreciation Rs m13,2299,122 145.0%   
Interest Rs m1,5941,525 104.5%   
Profit before tax Rs m12,22235,349 34.6%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m-7083 -84.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7989,785 18.4%   
Profit after tax Rs m10,35425,575 40.5%  
Gross profit margin %16.925.7 65.9%  
Effective tax rate %14.727.7 53.1%   
Net profit margin %7.114.6 48.4%  
BALANCE SHEET DATA
Current assets Rs m87,370119,542 73.1%   
Current liabilities Rs m33,08161,206 54.0%   
Net working cap to sales %37.133.3 111.3%  
Current ratio x2.62.0 135.2%  
Inventory Days Days8776 114.4%  
Debtors Days Days6290 69.3%  
Net fixed assets Rs m111,567131,660 84.7%   
Share capital Rs m1,609903 178.1%   
"Free" reserves Rs m123,645134,073 92.2%   
Net worth Rs m125,254134,976 92.8%   
Long term debt Rs m36,45456,478 64.5%   
Total assets Rs m209,532266,073 78.7%  
Interest coverage x8.724.2 35.9%   
Debt to equity ratio x0.30.4 69.6%  
Sales to assets ratio x0.70.7 106.2%   
Return on assets %5.710.2 56.0%  
Return on equity %8.318.9 43.6%  
Return on capital %8.519.3 44.1%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06681,885 62.4%   
Fx outflow Rs m17,67821,506 82.2%   
Net fx Rs m33,38860,378 55.3%   
CASH FLOW
From Operations Rs m23,82441,148 57.9%  
From Investments Rs m-13,127-25,287 51.9%  
From Financial Activity Rs m-13,2394,332 -305.6%  
Net Cashflow Rs m-2,47820,193 -12.3%  

Share Holding

Indian Promoters % 16.0 46.6 34.3%  
Foreign collaborators % 20.8 0.2 10,400.0%  
Indian inst/Mut Fund % 12.2 11.3 108.0%  
FIIs % 23.7 31.9 74.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.1 259.4%  
Shareholders   161,166 98,259 164.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 19, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS